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ABSTRACT

Depression is one of the most prevalent risks to human productivity and life worldwide,
decreasing life expectancies by up to 7-10 years. The hypothalamic-pituitary-adrenal (HPA)
axis plays a primary role in stress response through the regulated secretion of the
glucocorticoid hormone cortisol. Diseases of cortisol dysregulation such as Cushing’s
syndrome (hypercortisolemia) and Addison’s Disease (hypocortisolemia) are both
associated with depression. Based on this we, and others, have hypothesized that mutations
in the genes for the glucocorticoid receptor (GR), the closely related mineralocorticoid
receptor (MR), and regulatory proteins associated with cortisol or GR function may
contribute to depression in the absence of hyper- or hypo-cortisolemia. Our study
investigated the genotypic frequency in the clinical population of several single nucleotide
polymorphisms (SNPs) that affect GR and MR sensitivity to cortisol binding. Buccal swab
DNA samples were acquired from patients clinically diagnosed with depression and from a
random population. Extracted DNA was analyzed utilizing multiple allele-specific
polymerase chain reactions to determine genotypic frequency of SNPs associated with
hypersensitivity or resistance to cortisol. In addition, patients completed measures of
depression (BDI) and anxiety (STAI-T, STAI-S). While there was no significant difference
between genotypes for BDI measures, patients carrying a TthIII mutant allele for the GR had
significantly higher scores on the STAI-T inventory. Further understanding the role of
geneotypic variation in cortisol function could lead to more specific and targeted therapies
for depression with the goal of improving patient outcomes.
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INTRODUCTION
Stress and the resulting neuroendocrine responses have been evolutionarily essential to
survival, accessing energy reserves and instigating a myriad of adaptations in physiology
and behavior that relieve the adverse stressor (DeRijk & de Kloet, 2005). In contrast, longterm prolonged stress can additionally affect function of physiological processes such as the
sympathetic nervous system and immune response (Mackin & Young, 2004) and disrupt or
degrade cellular development, communication and overall health. Further, abnormal
functioning or impaired regulation of stress response systems and their subsequent products
has been strongly linked to physiological and psychiatric disorders including Major
Depressive Disorder (Dougherty, Klein, Olino, Dyson, & Rose, 2009) This is particularly
true of early-developmental adversity, which predisposes one to depressive symptoms and
conditions (Cai, 2015)(Brown et al., 1987).
Diagnosis of depression is determined by presence of 5 of 9 depressive symptoms, with one
being either depressed mood or anhedonia. These symptoms as determined by DSM-5 are:
1. Depressed mood;
2. Markedly diminished
interest or displeasure
3. Increase or decrease
in either weight or
appetite
4. Insomnia or
hypersomnia

5. Psychomotor
agitation or
retardation
6. fatigue or loss of
energy
7. feelings of
worthlessness or
inappropriate guilt

8. diminished ability to
think or concentrate,
or indecisiveness
9. recurrent thoughts of
death or recurrent
suicidal ideation
(Fried & Nesse, 2015).

Due to the heterogeneity of the disease, there are several subtypes of depression with
different pathogenesis and treatment options, though their biological basis has yet to be fully
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explained (Drysdale, 2017). Major Depressive Disorder (MDD) is one of the most prevalent
risks to human life and productivity worldwide. Life expectancy for afflicted populations is
estimated to be 7-10 years less than the general population, with a 1.8 fold mortality rate,
partially due to increased risk of suicide (Otte, Gold, & Pennix, 2016). Clinical and public
efforts to decrease suicide rates, though widespread, have been notoriously inconsistent,
with less than a third of patients seeing clinical improvement (Thase & Rush, 1997).
The mechanism for human stress response is the hypothalamic-pituitary-adrenal (axis)
(Figure 1). Upon encountering a stressor, (defined as any threat- physical or perceived, acute
or prolonged- to the well-being of an
organism (Jacobson, 2014)) peptides
corticotropin-releasing-hormone
(CRH) and arginine vasopressin
(AVP) (which serves to potentiate
CRH function) are secreted by cells
within the paraventricular nucleus of
Figure 1. Diagram of the major components of the
Hypothalamic Pituitary Adrenal (HPA) Axis when
facilitating a stress response in the human body.
(Justin Salm ‘16)

the hypothalamus, which in turn signal
the release of adrenocorticotropic
hormone (ACTH) from the pituitary

glands. This triggers the release of glucocorticoids, the workhorses of the stress response,
from the adrenal glands. Glucocorticoids, namely corticosterone and cortisol in human
endocrine systems, serve a variety of purposes, including mobilization of glucose, gene
expression alterations, and negative inhibition of HPA-axis functionality (Mackin & Young,
2004). They primarily bind to two intracellular corticosteroid receptors within the cytosol,
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the type I mineralocorticoid receptor (MR) and the type II glucocorticoid receptor (GR)
(Klok, et al., 2011).
Mineralocorticoid receptors help to regulate electrolyte balance in the kidneys, where
glucocorticoids are inactivated by 11-betahydroxysteroid dehydrogenase type 2 (11HSD-2)
(DeRijk & de Kloet, 2005). However, MR are primarily located in limbic areas of the brain
such as the hippocampus, amygdala and hypothalamus and have a high affinity for cortisol
binding (Herbert, 2013). Because of this, they are constantly saturated with cortisol, even
during basal (non-stress) conditions, and function to regulate the amount of free plasma
cortisol. A low affinity MR has recently been discovered, and though the role of this
receptor has yet to be fully determined, this finding suggests that MR may play a larger role
in stress response regulation that previously thought (Klok, et al., 2011). The low affinity
GR (at a tenth of the affinity of high affinity MR) is present more ubiquitously than MRs
throughout the brain and body and is highly concentrated in the hippocampus and prefrontal
cortex (PFC), and becomes activated only when cortisol levels are particularly high due to
stress response. GR can also bind at the peaks of the circadian cycle, and terminates
extended HPA axis activity at several points through feedback inhibition of CRH,
vasopressin and ACTH production (Velders, et al., 2011).
The HPA axis under basal conditions fluctuates in diurnal rhythms, governed by the
hypothalamic suprachiasmatic nucleus, that vary in frequency and amplitude, with the
highest peaks generally occurring in the morning approximately 45 minutes after waking
(Sharpley, et al., 2016) (Jacobson, 2014). Alterations in these rhythms, particularly
hyperactivity of the HPA axis and the resulting hypercortisolemia have been strongly linked
to MDD as well as other disorders such as PTSD (Savic, Knezevic, Damjanovic, Antic, &
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Matic, 2014), with hypercortisolemia present in about 50% of the depressed patient
population, with even higher percentages for the melancholic depression subtype
(Dougherty, Klein, Olino, Dyson, & Rose, 2009). Additionally, normalization of HPA
activity has been found to precede clinical recovery (Holsboer, 2000) (Sarubin, et al., 2016).
This research suggests that elevated cortisol levels (in amplitude of cortisol pulses and not in
frequency), particularly in the morning, can serve as a predictor of susceptibility to MDD
and a marker for depression. (Herbert, 2013) (Jacobson, 2014). Hypocortisolemia,
characterized by prolonged low concentrations of cortisol occurring primarily after periods
of extreme elevation, has also been found to present in approximately 25% of patients with
stress-related disorders (Sharpley, et al., 2016), and threatens lowered immune function.
Both hypo- and hyper-cortisolemia have also been associated with metabolic syndrome
(which presents with insulin resistance, abdominal obesity and high blood pressure among
other symptoms) and prolonged high cortisol levels can cause Cushing’s Syndrome, and
patients with Cushing’s Syndrome have increased incidence of depression (Vammen, et al.,
2014), though that data may be correlational or be related to the impacts on quality of life by
Cushing’s itself. Research has linked metabolic syndrome and depression, with cortisol as
the common factor, though results have been inconsistent as to the exact association. One
study found that hypercortisolic, depressed patients are at increased risk for metabolic
syndrome, suggesting that HPA axis hyperactivity and/or GR or MR abnormalities may be
the link. However, this research has not yet been widely replicated (Vogelzangs, et al.,
2009).
HPA-axis modulation and neuroendocrine fluctuations in Depression
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Hyperactivity along the HPA-axis has been measured by observations of all locations of
neuroendocrine activity along the axis. Depressive patients have been found to have several
HPA changes including increase in CRH-secreting neurons in the limbic brain, increase in
frequency and amplitude of ACTH secretory pulses and HPA dysregulation measurement
via the CRH stimulation test and dexamethasone suppression test (DST) (Sher, 2003).
However, the clinical ability of the DST alone in depression diagnosis has been insufficient
and is primarily used in diagnosis of Cushing’s syndrome. Cortisol also interacts with brain
functions that control mood, behavior, (PFC) as well as memory and recall (hippocampus),
where it affects neurotransmitters and neuropeptides in brain circuits.
Because modulation of HPA axis activity is primarily controlled by corticosteroid receptors
binding and negative feedback, they are essential targets of research for understanding HPAaxis dysregulation and prolonged glucocorticoid elevation. Other potential factors are pglycoprotein membrane transporters that exclude glucocorticoids from cells, and type 1 and
2 isoforms of 11β-hydroxysteroid dehydrogenase (11 β HSD) which modulate
glucocorticoid levels via conversion of cortisol between its active state (cortisol) and
inactive state (cortisone) 11 β HSD inhibition results in increased ACTH, implying that
activation of cortisone allows feedback inhibition of ACTH and HPA axis regulation
(Jacobson, 2014). Twin research has found some evidence that elevated morning cortisol is
moderately heritable, which suggests a genetic cause for HPA axis abnormalities.
Single-Nucleotide-Polymorphisms in HPA-Axis Modulators
Polymorphisms are common mutations throughout DNA, and consist of misplacement of
nucleotides. Single Nucleotide Polymorphisms (SNPs), true to the name, are instances of
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substitution of one nucleotide for another, and can have a multitude of effects depending on
the nucleotides substituted, location on the gene, and what the gene is coding for. SNPs in
genes that code for HPA axis and glucocorticoid regulation mechanisms can have varying
degrees of alteration of hormone sensitivity and activity levels. Several SNPs have been
identified that impact GR, MR and 11 β HSD function.
β HSD type 1 and 2
Ninety-five percent of cortisol is bound in the blood by corticosteroid-binding-globulin
(CBG) as protection from degradation by liver P450 enzymes, but free cortisol passively
diffuses across the membrane where 11 β HSD type 1 (activation from cortisone to cortisol)
and 2 (conversion from cortisol to the inactive cortisone) regulate cytosolic concentrations.
Changes in function of these enzymes can significantly affect cortisol levels. 11 β HSD type
1 is coded for by HSD11B1, and common SNPs have been associated in some studies with
certain symptoms of metabolic syndrome, including hypertension, insulin resistance and
type 2 diabetes (Fichna, et al., 2016).
Glucocorticoid Receptor Genotypes
The GR is a ligand dependent transcription factor protein known as a nuclear receptor. The
GR coding gene (NR3C1) is located on chromosome 5q21, and is approximately 150 kB
long (Koper, van Rossum, & van den Akker, 2014) The GR protein itself is composed of
three domains, the N-terminal transactivation domain (NTD), which recruits and binds
transcription factors and co-regulators, a domain to which DNA binds (DBD) and a Cterminal domain for ligand-binding (LBD) (Kadmiel & Cidlowski, 2013). Without the
presence of glucocorticoids the GR remains bound in the cytoplasm of the cell by chaperone
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proteins and others that maintain the inactive state as well as accessibility for glucocorticoid
attraction and binding. Upon ligand binding to the GR, it undergoes a transformational
change and is translocated to the nucleus, where it induces or represses target gene
expression through interaction with Glucocorticoid Response Elements (GREs) (Figure 2).
Glucocorticoid receptors are
present in nearly every cell of the
body, and have an incredibly
diverse range of functions, as well
as vast genetic variation due to an
extensive list of identified SNPs. As
of 2014 there were over 3000, and
Figure 2. GR signaling pathway (Koper, van Rossum, &
van den Akker, 2014, p. 64)

many more have been identified.
However, most of these have a

minor allele frequency of less than 1% and therefore are statistically irrelevant.
A small number with higher minor allele frequency have also been found to alter
glucocorticoid sensitivity (Koper, van Rossum, & van den Akker, 2014). Four of the most
significant are Tth111I, ER22/23EK, N363S and BclI. TthIII1 (rs10052957) is a C → T
substitution, and has been associated with elevated basal cortisol levels, but some research
has suggested this effect is due to haplotype association with other GR SNPs, including
ER22/23K. ER22/23EK (rs6189 + rs6190) results from two single point substitutions on
codons 22 and 23 and affects the secondary structure of the GR mRNA, favoring a less
active start codon, which has been clinically associated with reduced GR sensitivity. N363S
(rs56149945) is a A → G substitution, and has been associated with GR hypersensitivity and
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enhanced cortisol suppression (Wust, et al., 2004). Lastly, BclI is characterized by a C → G
substitution that has been associated with GR hypersensitivity (Koper, van Rossum, & van
den Akker, 2014).
Mineralocorticoid Receptor Genotypes
The MR is anatomically similar to the GR, but differs in its high affinity for binding
glucocorticoids throughout the diurnal cortisol cycle, and is not as widely spread throughout
the body as GR, being found primarily in the limbic brain and highly concentrated in the
hippocampus. Because of its high affinity, the GR controls the onset and threshold of HPA
axis stress response. There are two known significant MR SNPs, rs207 (rs2070951) and rs55
(rs5522) (Leeuwin, et al., 2011). Rs207 is a C → G substitution associated with higher
morning cortisol levels (Mutz, Zyriax, Bondy, Windler, & Otte, 2011) while rs55 is an A →
G substitution associated with MR reduced glucocorticoid sensitivity.

9

Figure 3. Glucocorticoid Receptor coding gene (NR3C1). Circled are the locations of the Bcl1 and
TthIII1 SNPs. Image obtained from https://www.researchgate.net/figure/293801264_fig2_Fig-2Glucocorticoid-receptor-gene-NR3C1-structure-and-functional-polymorphisms

Table 1 GR, MR and 11BHSD glucocorticoid hypersensitivity or resistance SNP Oligonucleotides

Official name Colloquial name

Phenotype

Gene
Name

WT/MUT

Population Freq (minor allele, ie
mutant)

rs41423247

Bcl I

Hypersensitivity

NR3C1 G/C

C=0.2546

rs56149945

N363S

Hypersensitivity

NR3C1 A/G

C=0.0208/2520

rs10052957

TthIII1

Resistance

NR3C1 A/G

A=0.2212/1108

RS12086634 RS120

Hypersensitivity

HSD11-B1 T/G

G=0.2066 (ExAC)

RS846910

RS84

Resistance

HSD11-B2 G/A

A=0.1010/506

RS2070951

RS207s

Hypersensitivity NR3C2

C/G

G=0.4490/48980 (ExAC)

RS5522

Rs55s

Resistance

T/C

C=0.1188/14428 (ExAC)

NR3C3
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METHODS
Participants
Buccal cheek cells were collected at Albany Medical College from 30 psychiatric patients,
along with their scores for Beck Depression Inventory (BDI) as well as State and Trait
Anxiety Inventories (STAI-S, STAI-T) and salival samples. Approval for this patient study
was obtained from Albany Medical College’s Institutional Review Board for patient
samples. The purpose of the study and the rights of the patient were explained, and informed
consent was obtained prior to sample collection. The patient was given a buccal swab with
which they were instructed to rub their cheeks and gums for 15 seconds, then place swabside first into a 15 mL centrifuge tube. Then they were instructed to deposit as much saliva
as they could produce into a second 15 mL centrifuge tube. The tubes were then labeled
with the patients’ Top ID number and stored at 4 º C until DNA extraction.
DNA extraction
DNA was extracted from the buccal swabs as per the Environmental Health Perpect Protocol
(107:517-520) (1999.) The swab handle was cut off and placed inside a 1.5 mL
microcentrifuge tube, to which 600 mL of 50 Mm NaOH was added. The tube was then
closed and vortexed for 10 minutes, then heated at 95 º C for 10 minutes in a heating block.
120 uL 1M Tris (pH 8.0) was then added to the tube, and the brush was removed and
discarded. The sample was then split into two tubes for storage, 100 uL at 4 º C and the
remainder in the second tube at – 20 º C.
Primer optimization
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Before genotypic analysis, SNP primers had to be optimized for allele-specific Polymerase
Chain Reaction (PCR). Primers were first determined by identification of the SNP within the
gene and production of wild-type specific, mutant specific and common primer sequences
by a Web-Based Allele Specific Primer (WASP) Program. They were then ordered from
Integrated DNA Technologies, Inc. (Skokie, IL) based on this WASP generation.
Primer function is dependent on several factors including temperature, cycle, Mg+ presence
and concentration, and the brands of the other PCR components, and required many trials
manipulating these variables for each SNP in this study. Primer sets for two MR
polymorphisms were optimized effectively- Bcl1 (rs41423247), a hypersensitivity SNP and
TthIII (rs10052957) a resistance SNP.

Figure 4 Output of WASP Generation. SNPs in bold were successfully optimized for the PCR
protocol.

PCR using allele-specific primers
PCR occurs within a thermal cycler, utilizing multiple cycles of varying temperatures to
denature DNA template and then replicate specific gene sequences. In allele-specific PCR,
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primers included will only bind to the template if a certain allele is present, and therefore
can be used to determine the presence of a certain SNP or wild-type allele. Three WASP
generated allele-specific primers are included, including two forward primers with varying
tails (WT and MT) and a common reverse primer. Each PCR reaction tube contained a total
of 15 uL (table 2).

Table 2. Reagent Quantity in PCR Reactions

Reagent

Quantity (uL)

1) Deionized Water

5.125 ul

2) Buffer

1.5 ul

3) dNTPs

0.3 ul

4) Common Primer

1.5 ul

5) DNA taq polymerase

0.075 ul

6) WT or MUT Primer

1.5 ul

7) Q Solution

3 ul

7) Patient Template

2 ul

The PCR reactions were run in a Bio Rad C1000 Thermal Cycler. The conditions are shown
in Table 3.
Table 3. Thermal Cycler PCR Conditions for BclI and TthIII1 SNPs.

BclI

TthIII1

95°C

95 °C

Primer Annealing Temperature 56°C

61 °C

Primer Extension Temperature

72°C

Denaturation Temperature

Gel Electrophoresis

72°C
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To visualize PCR reaction products, 3 uL EZ vision dye was added to each of the PCR
reactions, and they were run through a 2% agarose gel at 200 V for 40 minutes. The gel was
then visualized under UV light to check for the presence of bands. The band size was
compared against a 100 bp ladder. Example images of visualized successful and failed trials
can be seen in Appendix A.
Data Analysis & Statistical Testing

ANOVA analysis of polymorphisms and psychological testing information was performed
using JMP v13 (SAS, Cary, NC).

Phone: 919.677.8000.
RESULTS
Prevalence of the SNPs
Genotyping was determined for each of the patients for BClI and TthIII1 based on the
protocols described above, and genotypic frequency of the alleles was compared to the
reported population (figure 3). For the TthIII1 SNP, the psychiatric population had a higher
MT allele frequency that the reported population, while BCl1 did not vary much between the
populations, with a slightly higher prevalence of the MT allele.

14

Figure 5. Genotypic frequency of psychiatric population compared to reported population for the
Bcl1 and Tthiii1 SNPs.

Associations between allelic frequencies and psychiatric parameters
ANOVAs were performed using JMP with a p < 0.05 significance criterion to compare
genotypic frequencies for TthIII1 with psychiatric inventory scores for BDI, STAI-S and
STAI-T. For the Trait Anxiety Inventory (STAI-T) significant difference was observed for
patients carrying the MT allele (heterozygous or homozygous mutant genotype) compared to
the homozygous WT sample, with scores higher with presence MT allele. For the State
Anxiety Inventory, a significant difference was found between the heterozygous and
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homozygous wild-type groups. There was no significant difference found for the Beck
Depression Inventory between any of the groups (p > 0.05) (figure 4).

Figure 6. Depression inventory scores were compared across genotypic groups. A
significant difference was found between groups for STAI-T for patients that carry the
mutant allele (heterozygous and homozygous mutant) and for STAI-S for the heterozygous
group compared to the homozygous wild-type.

DISCUSSION
The initial hypothesis was that the psychiatric population would have a lower allelic
frequency of hyperactivity SNPs (BCl1, N363S, RS207) and higher allelic frequency of
resistance SNPs (TthIII1, RS84) compared to the population. As a result, it was
hypothesized that for this sample, the resulting over-activity of the HPA axis will result in
elevated basal cortisol levels in the psychiatric patient sample. These initial hypotheses
failed to consider the fact that resistance and hypersensitivity SNPs have different effects on
the HPA axis depending on the receptor that they code for, so while a higher allelic
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frequency was found for the resistance SNP TthIII1, hyperactivity of GR SNPs may not
result in higher basal cortisol levels. Additionally, tests were not performed for basal cortisol
levels, so this hypothesis was unresolved. For TthIII1, however, these hypotheses are
consistent with the literature and supported by these data.
Genotypic frequencies
The results suggest a difference in genotypic frequency of the TthIII1 MT allele between the
psychiatric population and the normal population (figure 3), which suggests a possible role
of the TthIII1 in modulating GR activity. These data are consistent with the implications of
the literature associating TthIII1 with elevated basal cortisol levels (Wust, et al., 2004). As a
GR SNP associated with resistance of the GR to binding cortisol, this mutation may result in
less negative feedback inhibition of the GR on the HPA axis, resulting in greater overall
cortisol production. The resulting hypercortisolemia has been strongly linked to psychiatric
conditions such as MDD and PTSD (Sarubin, et al., 2016).
Associations between SNP prevalence and psychiatric parameters
Of note in the results was the finding of significantly higher differences in scores between
genotypic groups for TthIII1 under State-Trait Anxiety Inventories, suggesting that the
TthIII1 SNP may cause a difference in the presentation of anxiety within the disease, while
there were no significant differences between any of the genotypic groups for BDI scores
(figure 4). These results have concerning clinical implications, as cutoff values for
depression diagnosis are based on sum-scores from BDI and other rating scales such as the
Hamilton Rating Scale for Depression (HRSD), without consideration of the heterogeneity
of the disease between patients.
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Fried and Nesse (2015) argue that the pervasive use of sum-scores to estimate depression
severity has stagnated progress in treatment of depression by obfuscating key insights into
the presentation of the disease, such as biomarkers of depressive symptoms. Indeed, no
biomarker has been found to be significant across the entire depressive population, though
much research has been applied to identify this elusive depressive biomarker. A genomewide association study with 34,549 subjects did not find a biomarker that was significant
across the genome. As a result of this unsuccessful search, no biological tests have been
added to depression criteria sets for the DSM-V. Fried and Neese suggest that analysis of
specific symptoms and more specialized scales for measurement of these symptoms can
allow for personalization of care and therefore increased effectiveness of clinical treatment.
The finding in the present study of significant differences between genotypic groups under a
specific scale (STAI-T) with no significance under the sum-scale (BDI) supports this
assertion (2015).
Conclusions and Directions for Future Research
Primer optimization trials were only consistently successful for the alleles of two SNPs
analyzed above (Bcl1 and Tth111I), so genotypic analysis of other GR as well as MR and
11B-HSD SNPs was not complete for the patient population. The failure to optimize these
primers is likely due in part to modifications of DNA isolation, PCR and gel electrophoresis
protocol over trials to increase efficiency and clarity of products. Future research will use
the improved protocol described above to optimize these alleles and generate a complete
genotypic database for the psychiatric sample with which to conduct further statistical
analysis.
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Given the results of this study, a SNP of particular interest for further research is ER/EK.
Though TthIII1 has been commonly associated with higher basal cortisol levels and altered
promoter activity, some research suggests this effect may be due to haplotype associations
with other GR SNPs such as Bcl1 or ER/EK (Koper, van Rossum, & van den Akker, 2014).
Though no associations were found between genotypic frequencies of Bcl1 and TthIII1 for
our population, suggesting an autonomous effect of TthIII1, the same cannot be determined
for ER/EK given the current data set for our sample. Further, given the role of the GR in
regulating HPA axis activity, basal cortisol levels may provide valuable insight on SNP
function and differentiation. Basal cortisol levels for patient samples can be measured by
cortisol assays, and quarterly follow up testing can track patient response to treatment, as
normalization of HPA-axis activity has been found to precede clinical recovery (Holsboer,
2000) (Sarubin, et al., 2016). If, as the results suggest, polymorphisms such as TthIII1 affect
inhibition of HPA-axis activity -- subsequently mediating glucocorticoid release-differences in basal cortisol levels may be found between genotypic groups for these SNPs.
Lastly, these data emphasize the need for personalization of treatment based on disease
heterogeneity. Future research should compare specific BDI Inventory scores between
genotypic groups, to determine the extent to which depression sum scores conceal important
symptomatic differences in depressive patients. Given clinical obfuscation of heterogeneity
of the disease, the failure of biological research to identify significant biomarkers for the
entirety of the depressive population is rendered unsurprising. Alternatively, research may
be able to discover biomarkers for depressive groups separated by clinical symptomatic
determination. These biomarkers can then serve as targets for drug development, increasing
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effectiveness of pharmacological treatment and decreasing side effects that have been found
to create severe and pandemic symptoms which further stagnate recovery of quality of life.
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